LLY
Eli Lilly and Company
LLY has the edge over PHG overall, supported by stronger modeled upside and stronger fundamentals.
PHG
Koninklijke Philips N.V.
PHG's outlook is improving, though it still trails on the overall score.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
PHG Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Strong | |
| Healthy | |
| Healthy |
PHG's profitability, cash flow and balance sheet are currently healthy, and its revenue is stable.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY has the edge over PHG in the historical PE scenario, which offers more potential upside but is not a forecast.
PHG PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 7x | $9.06 | -70% |
| Current | 23x | $30.05 | — |
| Fair | 29x | $37.91 | +26% |
| Expensive | 40x | $51.41 | +71% |
Historical ranges are pointers, not guarantees.
PHG's PE is 23x, but its earnings don't support one, so it isn't a reliable read right now.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
PHG Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Growth | |
| Growth | |
| Improving | |
| Limited | |
| High |
Analysts expect earnings and revenue growth for PHG, with profitability improving.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over PHG on earnings, with more consistent year-over-year improvement.
PHG Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $1.29 | +579% |
| Q1 2026 | $1.12 | +155% |
| Q4 2025 | $1.03 | +$1.90 |
| Q3 2025 | $0.18 | +$0.61 |
| Q2 2025 | $0.19 | +$0.73 |
| Q1 2025 | $0.44 | +$1.43 |
| Q1 2024 | -$0.99 | +$1.60 |
| Q1 2023 | -$2.59 | -171% |
PHG's earnings per share have fallen from their peak: $1.29 over the past year, against $4.36 in late 2021.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over PHG on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over PHG on profitability, with a higher operating margin.
PHG Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $4.8B | +0.5% |
| Q1 2026 | $4.3B | -4.7% |
| Q4 2025 | $5.7B | +1.1% |
| Q3 2025 | $4.8B | -1.7% |
| Q2 2025 | $4.8B | -2.8% |
| Q1 2025 | $4.6B | -1% |
| Q4 2024 | $5.6B | -0.4% |
| Q3 2024 | $4.9B | -2.1% |
PHG's revenue fell from its 2020 peak and has held roughly level since: $4.8B last quarter, about level with the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 14% | +4.8 points |
| Q1 2026 | 6.2% | +2.4 points |
| Q4 2025 | 11% | +6.6 points |
| Q3 2025 | 7.7% | 0 points |
| Q2 2025 | 9.2% | -9.1 points |
| Q1 2025 | 3.8% | +24 points |
| Q4 2024 | 4% | +3.5 points |
| Q3 2024 | 7.7% | +2.7 points |
PHG's operating margin was 14% last quarter, up 4.8 points from the same quarter a year ago, near the top of its range since 2019.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over PHG on cash flow, with more consistent year-over-year improvement.
PHG Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $243.3M | -3.9% |
| Q1 2026 | $129.9M | +$1.3B |
| Q4 2025 | $1.5B | +$1.5B |
| Q3 2025 | $287.7M | +$287.7M |
| Q2 2025 | $253.3M | +$331M |
| Q1 2025 | -$1.2B | -$776.3M |
| Q4 2024 | $0 | $0 |
| Q3 2024 | $0 | $0 |
PHG's free cash flow is usually positive and has bounced back after one negative quarter: $2.1B over the past year, against −$902M the year before.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over PHG on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
PHG Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | +44K shares |
| 1 year | +1.2% | +11.9M shares |
| 3 years | +2.3% | +22M shares |
| 5 years | +1.3% | +12.3M shares |
| Available history | +0.6% | +6.2M shares |
PHG has 969M diluted shares, up 1.2% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2026 | $75.5M |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | — |
| Q3 2024 | — |
PHG spent $76M buying back its own shares over the past year, after none the year before.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY has the edge over PHG on leverage, with a lower net debt burden relative to earnings.
PHG Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 1.9x | Healthy |
| Q1 2026 | 2.0x | Moderate |
| Q4 2025 | 2.0x | Moderate |
| Q3 2025 | 3.0x | Moderate |
| Q2 2025 | 3.5x | Elevated |
| Q1 2025 | 3.5x | Elevated |
| Q4 2024 | 6.2x | High |
| Q3 2024 | -1.5x | Net Cash |
PHG's net debt is about 1.9 years of its operating earnings (EBITDA), down from 3.5 years a year ago.
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
PHG Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 64.3 | Neutral |
| Stochastic | 84.8 | Overbought |
PHG's weekly RSI is 64 (neutral) and its Stochastic is 85 (overbought).
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
PHG PE vs Healthcare Sector
| Metric | PHG | Sector median | Relative |
|---|---|---|---|
| PE | 23x | 26x | 9.8% below |
| PE % | 29 | 29 | Same percentile |
PHG has the edge over LLY on valuation relative to its sector.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY is in an uptrend: it's above all five of its weekly moving averages, and 79% above its 200-week average.
PHG Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $26.6 | 13% above |
| 20 week MA | $26.6 | 13% above |
| 50 week MA | $27.4 | 9.9% above |
| 100 week MA | $26.7 | 13% above |
| 200 week MA | $24.5 | 23% above |
PHG is in an uptrend: it's above all five of its weekly moving averages, and 23% above its 200-week average.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over PHG on returns for 2026, with the stronger performance.
PHG Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $44.5 | $49.8 | +12% |
| 2021 | $49.8 | $33.6 | -33% |
| 2022 | $33.6 | $14.9 | -56% |
| 2023 | $14.9 | $22.6 | +51% |
| 2024 | $22.6 | $25.6 | +13% |
| 2025 | $25.6 | $27.1 | +6% |
| 2026 YTD | $27.1 | $30.1 | +11% |
PHG has finished higher in four of the last six years. It's up 11% so far in 2026.